Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis

Next Previous
X
Search
Trial Profile

An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Invimestrocel (Primary)
  • Indications Adult respiratory distress syndrome; Pneumonitis; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ONE-BRIDGE; ONE-BRIDGE ARDS
  • Sponsors Healios

    • Most Recent Events

    • 15 Jan 2024 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2022 According to an Athersys media release, Healios provided updates on this trial in Japan on an exclusive basis
    • 30 Nov 2021 Pooled data analysis of the MUST-ARDS and this study presented in the Athersys Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top